Persephone Biosciences vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
Persephone Biosciences uses gut microbiome profiling and synthetic biology to develop cancer immunotherapy response predictors and novel therapeutics; founded 2017 in San Diego; received BARDA funding for microbiome-based diagnostics;
About
Persephone Biosciences is a biotechnology company founded in 2017 by Stephanie Culler and Chris Calvert and based in San Diego, California. The company focuses on decoding the human gut microbiome to develop diagnostics and therapeutics in oncology and neonatal health. Its core thesis is that the composition of a patient's microbiome significantly affects how they respond to cancer immunotherapies such as checkpoint inhibitors — a hypothesis supported by a growing body of peer-reviewed clinical research. Persephone's diagnostic platform aims to predict immunotherapy response from a patient's microbiome signature prior to treatment initiation.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.